Key Points
- uniQure insider Walid Abi-Saab sold 45,000 shares on May 8 at an average price of $25.06, generating about $1.13 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The transaction reduced Abi-Saab’s stake by 20.96%, leaving him with 169,669 shares valued at roughly $4.25 million after the sale. He had also sold 808 shares earlier in March.
- uniQure reported mixed quarterly results, beating earnings expectations with EPS of -$0.85 but missing revenue estimates at $3.56 million. The stock was up 5.3% on the day, and analysts currently rate it Moderate Buy with an average price target of $42.83.
uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Walid Abi-Saab sold 45,000 shares of the company's stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company's stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Walid Abi-Saab also recently made the following trade(s):
- On Wednesday, March 4th, Walid Abi-Saab sold 808 shares of uniQure stock. The shares were sold at an average price of $9.06, for a total transaction of $7,320.48.
uniQure Stock Up 5.3%
QURE opened at $29.10 on Wednesday. The firm has a 50-day simple moving average of $17.21 and a two-hundred day simple moving average of $24.01. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a market capitalization of $1.84 billion, a PE ratio of -8.36 and a beta of 0.87. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Analysts forecast that uniQure N.V. will post -3.68 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Wolfe Research assumed coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a "peer perform" rating on the stock. Chardan Capital increased their target price on shares of uniQure from $31.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. Leerink Partners reissued an "outperform" rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Finally, Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of "Moderate Buy" and an average price target of $42.83.
Get Our Latest Stock Report on uniQure
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Sigma Planning Corp purchased a new position in uniQure during the 1st quarter valued at about $276,000. Stephens Inc. AR purchased a new position in uniQure during the 1st quarter valued at about $182,000. Y Intercept Hong Kong Ltd increased its position in uniQure by 148.9% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 113,952 shares of the biotechnology company's stock valued at $1,863,000 after purchasing an additional 68,174 shares during the period. Patriot Financial Group Insurance Agency LLC purchased a new position in uniQure during the 1st quarter valued at about $275,000. Finally, Cannon Global Investment Management LLC purchased a new position in uniQure during the 1st quarter valued at about $199,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
